Share Now

Additional Information

TauroLock™-U25.000 is approved to be instilled into catheter-based devices for central venous access in order to maintain patency of the device. Additionally, by creating a hostile environment to bacterial and fungal growth, the risk of catheter-related bloodstream infections (CRBSI) is reduced.

Ingredients / Specification:
TauroLock™-U25.000 contains substances to ensure patency and provide infection control in the device. Active ingredients in TauroLock™-U25.000 are taurolidine, citrate (4%), and urokinase (25.000 IU). The product is sterile filter processed and supplied as a clear, sterile, non-pyrogenic solution. Urokinase is delivered in a separate vial and is reconstituted with the content of the ampoule immediately before use. Each single-dose ampoule contains 5 mL.

TauroLock™-U25.000 is prepared by adding TauroLock™ into the vial containing urokinase to obtain a clear solution. After treatment (e.g. dialysis), the system is thoroughly flushed with saline (min. 10 mL). Then, the clear fluid is to be instilled into the device lumen by exactly respecting the filling volume. TauroLock™-U25.000 remains in the system until the next treatment. The solution must be aspirated before initiating the next treatment. Flush the device with 10 mL of saline.

TauroLock™-U25.000 is contraindicated for patients with a known allergy to taurolidine, citrate, or urokinase, or for patients currently taking medication with known adverse interaction with taurolidine, citrate, or urokinase.

TauroLock™-U25.000 must be stored at 15 – 25 °C. It must be neither transported nor stored under freezing conditions. The reconstituted solution must be used instantly.

Article-no. : TP-05

Description: TauroLock™-U25.000 catheter lock solution
5 mL vial (single-dose)

Packaging: 5 x 5 ml

Related Products


Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the  respective local health authority or contracted by the MAH to supply to the end users  on a named patient basis. Some products such  as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.

[elfsight_whatsapp_chat id='1']